Medical Pharmacology: Chapter 7: Hypertension — Clinical and Pharmacological Series -- Module: HTN-03 — First-Line Antihypertensive Drug Classes: Mechanisms, Selection, and Contraindications

Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-03 — First-Line Antihypertensive Drug Classes: Mechanisms, Selection, and Contraindications
Tier: Core Concepts (CC)

BEFORE YOU BEGIN

These Core Concepts questions build your foundational understanding of the five major first-line antihypertensive drug classes — thiazide diuretics, ACE inhibitors, ARBs, dihydropyridine calcium channel blockers, and beta-blockers. Work through each question before revealing the answer. Understanding the mechanism of each class and why it is selected or avoided in specific clinical settings is the foundation for everything that follows in Tiers 1 through 4.

1. Thiazide diuretics lower blood pressure through which primary mechanism?

A) Blockade of the sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, producing natriuresis and volume depletion
B) Blockade of the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, reducing sodium reabsorption and decreasing intravascular volume; with chronic use, a reduction in peripheral vascular resistance contributes to the sustained antihypertensive effect
C) Inhibition of carbonic anhydrase in the proximal tubule, reducing bicarbonate and sodium reabsorption and producing a mild alkaline diuresis
D) Competitive antagonism of aldosterone at the mineralocorticoid receptor in the collecting duct, reducing sodium reabsorption and potassium wasting
E) Blockade of epithelial sodium channels (ENaC) in the collecting duct principal cells, reducing sodium reabsorption independent of aldosterone

ANSWER: B

Rationale:

Thiazide diuretics block the NCC (sodium-chloride cotransporter) in the distal convoluted tubule — this reduces sodium reabsorption, increases urinary sodium excretion, and initially lowers BP through volume depletion; with chronic use, intravascular volume partially normalizes but BP remains lower due to a sustained reduction in peripheral vascular resistance, the mechanism of which is not fully characterized but may involve vascular smooth muscle changes; hydrochlorothiazide and chlorthalidone are the prototypical agents.

Option A: Option A is incorrect — NKCC2 blockade in the thick ascending limb is the mechanism of loop diuretics (furosemide, bumetanide, torsemide), not thiazides.
Option C: Option C is incorrect — carbonic anhydrase inhibition is the mechanism of acetazolamide, which is not used as an antihypertensive.
Option D: Option D is incorrect — aldosterone receptor antagonism in the collecting duct is the mechanism of spironolactone and eplerenone.
Option E: Option E is incorrect — ENaC blockade is the mechanism of amiloride and triamterene, the potassium-sparing diuretics.

2. Which of the following most accurately describes the mechanism by which ACE inhibitors lower blood pressure?

A) They block the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from binding and activating downstream vasoconstriction and aldosterone release
B) They inhibit the enzyme renin, preventing conversion of angiotensinogen to angiotensin I and reducing the entire downstream RAAS cascade
C) They inhibit angiotensin-converting enzyme, preventing conversion of angiotensin I to angiotensin II; the resulting reduction in angiotensin II decreases vasoconstriction, reduces aldosterone secretion, and lowers BP; ACE inhibition also reduces bradykinin degradation, raising bradykinin levels which contributes to vasodilation but also causes the class effect of dry cough
D) They block calcium entry into vascular smooth muscle cells through L-type voltage-gated calcium channels, reducing vascular tone and peripheral resistance
E) They activate the angiotensin II type 2 (AT2) receptor, which counterbalances AT1-mediated vasoconstriction and produces net vasodilation

ANSWER: C

Rationale:

ACE inhibitors block angiotensin-converting enzyme (ACE), which normally converts angiotensin I to angiotensin II; with ACE inhibited, angiotensin II levels fall, reducing its direct vasoconstrictive effects on vascular smooth muscle and its stimulation of aldosterone secretion from the adrenal cortex; ACE also degrades bradykinin, so ACE inhibition raises bradykinin levels — bradykinin contributes to vasodilation through nitric oxide and prostacyclin release, but also causes the dry cough that is a class effect of all ACE inhibitors.

Option A: Option A is incorrect — AT1 receptor blockade is the mechanism of ARBs (losartan, valsartan), not ACE inhibitors; ARBs do not affect bradykinin metabolism and therefore do not cause cough.
Option B: Option B is incorrect — renin inhibition is the mechanism of aliskiren, the only approved direct renin inhibitor.
Option D: Option D is incorrect — L-type calcium channel blockade is the mechanism of calcium channel blockers.
Option E: Option E is incorrect — ACE inhibitors do not directly activate AT2 receptors; the AT2 receptor does counterbalance AT1 effects but this is not the primary BP-lowering mechanism of ACE inhibitors.

3. How do ARBs differ mechanistically from ACE inhibitors in their effect on the renin-angiotensin-aldosterone system?

A) ARBs block renin secretion from juxtaglomerular cells, reducing angiotensin I production and providing more complete RAAS suppression than ACE inhibitors
B) ARBs block the AT1 receptor directly, preventing angiotensin II from binding regardless of how it was formed; because ACE is not inhibited, bradykinin is still degraded normally — ARBs do not raise bradykinin levels and therefore do not cause dry cough; angiotensin II levels actually rise due to loss of AT1-mediated feedback suppression of renin
C) ARBs and ACE inhibitors have identical mechanisms — both prevent angiotensin II formation and both raise bradykinin levels equally, producing the same side effect profile including dry cough
D) ARBs block the AT2 receptor specifically, which amplifies AT1-mediated vasoconstriction and produces a paradoxical increase in BP at low doses before the antihypertensive effect emerges
E) ARBs inhibit ACE through a non-competitive allosteric mechanism that is more complete than the competitive inhibition produced by ACE inhibitors, explaining their superior antihypertensive efficacy

ANSWER: B

Rationale:

ARBs (angiotensin receptor blockers) block the AT1 receptor directly — they prevent angiotensin II from binding to its primary receptor regardless of how angiotensin II was formed, including through non-ACE pathways such as chymase; because ACE itself is not inhibited, bradykinin is still degraded normally by ACE, bradykinin levels do not rise, and ARBs do not cause dry cough; furthermore, loss of AT1 receptor-mediated feedback inhibition of renin secretion causes a compensatory rise in renin and angiotensin II levels, but these cannot bind the blocked AT1 receptor.

Option A: Option A is incorrect — ARBs do not block renin secretion; renin levels actually rise due to loss of AT1-mediated feedback.
Option C: Option C is incorrect — ARBs and ACE inhibitors have different mechanisms; ARBs do not raise bradykinin and do not cause dry cough, which is a key clinical distinction.
Option D: Option D is incorrect — ARBs block AT1, not AT2; AT2 blockade is not the mechanism and ARBs do not cause paradoxical BP increase.
Option E: Option E is incorrect — ARBs do not inhibit ACE through any mechanism; they act at the receptor level downstream of ACE.

4. Dihydropyridine calcium channel blockers such as amlodipine lower blood pressure through which mechanism?

A) They block L-type voltage-gated calcium channels in vascular smooth muscle cells, reducing intracellular calcium, decreasing smooth muscle contraction, and lowering peripheral vascular resistance; dihydropyridines have much greater selectivity for vascular smooth muscle than for cardiac muscle, distinguishing them from non-dihydropyridine CCBs
B) They block L-type calcium channels equally in vascular smooth muscle and cardiac muscle, producing both vasodilation and significant negative inotropy and chronotropy that contribute to BP lowering
C) They block T-type calcium channels in the sinoatrial node, slowing heart rate and reducing cardiac output as the primary mechanism of BP reduction
D) They activate potassium channels in vascular smooth muscle, hyperpolarizing the cell membrane and indirectly reducing calcium entry through voltage-gated channels
E) They inhibit phosphodiesterase type 5 in vascular smooth muscle, raising cGMP levels and producing smooth muscle relaxation through a calcium-independent mechanism

ANSWER: A

Rationale:

Dihydropyridine CCBs (amlodipine, nifedipine, felodipine) block L-type voltage-gated calcium channels with high selectivity for vascular smooth muscle relative to cardiac muscle — reduced intracellular calcium in vascular smooth muscle cells decreases myosin light chain kinase activation, reducing smooth muscle contraction and peripheral vascular resistance; because of their vascular selectivity, dihydropyridines cause reflex tachycardia from vasodilation rather than the bradycardia seen with non-dihydropyridine CCBs.

Option B: Option B is incorrect — equal cardiac and vascular effects with significant negative inotropy and chronotropy describes the non-dihydropyridine CCBs verapamil and diltiazem, not dihydropyridines.
Option C: Option C is incorrect — T-type calcium channel blockade in the SA node is not the mechanism of dihydropyridine CCBs; some agents like mibefradil had T-type activity but were withdrawn.
Option D: Option D is incorrect — potassium channel activation is the mechanism of minoxidil and diazoxide (direct vasodilators), not CCBs.
Option E: Option E is incorrect — PDE5 inhibition raising cGMP is the mechanism of sildenafil; CCBs work through direct L-type channel blockade.

5. Which of the following most accurately describes how beta-blockers lower blood pressure?

A) Beta-blockers lower BP exclusively through cardiac effects — they reduce heart rate and myocardial contractility by blocking beta-1 receptors, decreasing cardiac output; the reduction in cardiac output directly lowers BP through the relationship MAP = CO × SVR
B) Beta-blockers lower BP through multiple complementary mechanisms — beta-1 blockade reduces heart rate and contractility (reducing cardiac output); beta-1 blockade at juxtaglomerular cells reduces renin secretion (lowering angiotensin II and aldosterone); and with chronic use, central sympatholytic effects and vascular adaptation contribute; the relative importance of each mechanism varies by agent and patient
C) Beta-blockers lower BP exclusively through renin suppression — blocking beta-1 receptors on juxtaglomerular cells prevents renin release, eliminating angiotensin II production and providing pure RAAS-mediated BP reduction
D) Beta-blockers lower BP through beta-2 receptor blockade in vascular smooth muscle, preventing catecholamine-mediated vasodilation and paradoxically reducing BP through elimination of vasodilatory tone
E) Beta-blockers lower BP through blockade of presynaptic beta-2 receptors on sympathetic nerve terminals, reducing norepinephrine release and decreasing sympathetic tone throughout the vasculature

ANSWER: B

Rationale:

Beta-blockers lower BP through multiple mechanisms — the primary acute effect is beta-1 blockade reducing heart rate and contractility, decreasing cardiac output; beta-1 blockade at juxtaglomerular apparatus cells reduces renin secretion, lowering angiotensin II and aldosterone with resulting volume reduction; with chronic use, resetting of baroreceptors and central nervous system effects contribute; different beta-blockers have different ancillary properties (ISA, alpha-blockade in carvedilol, vasodilatory effects in nebivolol through NO release) that modify the hemodynamic profile.

Option A: Option A is incorrect — while cardiac output reduction is important, it is not the exclusive mechanism; renin suppression and chronic vascular adaptation also contribute significantly.
Option C: Option C is incorrect — renin suppression is one mechanism among several; exclusive reliance on this mechanism understates the pharmacology.
Option D: Option D is incorrect — beta-2 blockade in vascular smooth muscle causes vasoconstriction (by blocking vasodilatory beta-2 receptors), not BP reduction; this is why non-selective beta-blockers can worsen peripheral vascular disease and cause unopposed alpha-mediated vasoconstriction in pheochromocytoma.
Option E: Option E is incorrect — presynaptic beta-2 receptor blockade reducing NE release is a secondary effect; it is not the primary mechanism of antihypertensive action.

6. Which electrolyte abnormality is most characteristically associated with thiazide diuretic use?

A) Hyperkalemia — thiazides block potassium excretion in the distal tubule by inhibiting the NCC transporter which also handles potassium secretion
B) Hypernatremia — thiazides cause free water retention through a mechanism involving impaired urinary dilution that raises serum sodium concentration
C) Hypokalemia — thiazides increase sodium delivery to the collecting duct where aldosterone-driven sodium reabsorption is coupled to potassium secretion; the increased distal sodium delivery enhances potassium excretion; volume contraction also stimulates aldosterone release which further promotes potassium wasting
D) Hypermagnesemia — thiazides impair magnesium excretion in the distal tubule, causing accumulation of magnesium in the serum
E) Hypercalciuria — thiazides increase urinary calcium excretion by blocking calcium reabsorption in the distal convoluted tubule, leading to calcium depletion

ANSWER: C

Rationale:

Hypokalemia is the most common and clinically significant electrolyte disturbance with thiazide diuretics — NCC blockade in the distal convoluted tubule increases sodium delivery to the downstream collecting duct; in the collecting duct, principal cells reabsorb sodium through ENaC in exchange for secreting potassium (driven by aldosterone); increased distal sodium delivery enhances this potassium secretion; additionally, volume contraction from natriuresis stimulates aldosterone release which further amplifies potassium wasting; clinically significant hypokalemia occurs in approximately 10–40% of patients on thiazides and warrants monitoring.

Option A: Option A is incorrect — thiazides cause hypokalemia, not hyperkalemia; potassium-sparing diuretics (spironolactone, amiloride) cause hyperkalemia.
Option B: Option B is incorrect — thiazides can cause hyponatremia (not hypernatremia) through impaired urinary dilution and free water retention, particularly in susceptible patients.
Option D: Option D is incorrect — thiazides cause hypomagnesemia (not hypermagnesemia) by increasing magnesium excretion in the distal tubule; hypomagnesemia can worsen hypokalemia by impairing potassium repletion.
Option E: Option E is incorrect — thiazides actually decrease urinary calcium excretion (hypocalciuria) by enhancing calcium reabsorption in the distal tubule; this is clinically useful in nephrolithiasis prevention and distinguishes thiazides from loop diuretics which increase calcium excretion.

7. A patient on an ACE inhibitor develops a persistent dry cough. The drug is discontinued. Which of the following most accurately explains the mechanism of ACE inhibitor-induced cough?

A) The cough results from ACE inhibitor-induced fluid retention causing subclinical pulmonary edema that irritates airway receptors
B) The cough results from ACE inhibitor-induced angiotensin II accumulation — excess angiotensin II activates AT1 receptors in bronchial smooth muscle causing bronchoconstriction and cough
C) The cough results from direct irritation of the vocal cords by the ACE inhibitor molecule — it is a local drug reaction unrelated to systemic pharmacology and resolves only after the drug is fully eliminated from vocal cord tissue over several weeks
D) The cough results from ACE inhibitor-induced accumulation of bradykinin in the airways — ACE normally degrades bradykinin; with ACE inhibited, bradykinin accumulates and activates bradykinin B2 receptors on airway sensory nerves, stimulating prostaglandin and substance P release that sensitizes cough receptors; this is a class effect of all ACE inhibitors and occurs in approximately 10–15% of patients, more commonly in women and East Asian patients
E) The cough results from ACE inhibitor-induced potassium retention causing hyperkalaemia that irritates the vagus nerve and triggers a reflex cough

ANSWER: D

Rationale:

ACE inhibitor-induced cough is mediated by bradykinin accumulation — ACE (kininase II) normally degrades bradykinin in the pulmonary circulation; with ACE inhibited, bradykinin accumulates and activates B2 receptors on airway C-fiber sensory nerves, stimulating release of prostaglandins and substance P that sensitize cough receptors in the airways; this dry, persistent, tickling cough is a class effect of all ACE inhibitors occurring in approximately 10–15% of patients overall, with higher rates (up to 30–40%) in women and East Asian populations; switching to an ARB (which does not affect bradykinin metabolism) eliminates the cough.

Option A: Option A is incorrect — ACE inhibitor cough is not caused by fluid retention or pulmonary edema; it occurs in patients with normal cardiac and pulmonary function.
Option B: Option B is incorrect — angiotensin II levels fall with ACE inhibition, not rise; and AT1 receptor activation in airways is not the cough mechanism.
Option C: Option C is incorrect — the cough is a systemic pharmacological effect mediated by bradykinin accumulation, not a local vocal cord irritation; it resolves within days to weeks of stopping the drug.
Option E: Option E is incorrect — ACE inhibitors can cause hyperkalemia but this is not the mechanism of cough; the cough pathway is specifically bradykinin-mediated.

8. Which of the following adverse effects is shared by both ACE inhibitors and ARBs?

A) Dry cough — both classes raise bradykinin levels through different mechanisms and both produce the same rate of cough as a class effect
B) Angioedema — both classes can cause angioedema, though ACE inhibitors cause it more commonly; ARB-associated angioedema occurs in a small percentage of patients, sometimes in those with prior ACE inhibitor angioedema, through a mechanism that may involve bradykinin or other vasoactive peptides
C) First-dose hypotension — both classes cause predictable severe hypotension with the first dose in all patients due to acute RAAS blockade regardless of volume status
D) Hyperuricemia — both classes raise uric acid levels by blocking renal uric acid excretion through inhibition of organic anion transporters in the proximal tubule
E) Dry cough and angioedema equally — the two classes are pharmacologically identical in their side effect profiles because both achieve complete RAAS blockade at the tissue level

ANSWER: B

Rationale:

Both ACE inhibitors and ARBs can cause angioedema, though the mechanisms and rates differ — ACE inhibitor angioedema is bradykinin-mediated (occurring in approximately 0.1–0.7% of patients) and is a class contraindication to all ACE inhibitors; ARB-associated angioedema is less common (approximately 0.1%) and may involve bradykinin or other vasoactive mediators; importantly, patients with prior ACE inhibitor angioedema have a small but real risk of ARB-associated angioedema and this cross-reactivity must be considered when switching; both classes share hyperkalemia and acute kidney injury risk through RAAS blockade.

Option A: Option A is incorrect — only ACE inhibitors cause dry cough through bradykinin accumulation; ARBs do not affect bradykinin metabolism and do not cause cough at rates above placebo — this is the primary pharmacological distinction between the two classes.
Option C: Option C is incorrect — first-dose hypotension can occur with both classes but is not predictably severe in all patients; it is more likely in volume-depleted patients or those on diuretics.
Option D: Option D is incorrect — hyperuricemia is associated with thiazide diuretics, not ACE inhibitors or ARBs; losartan (an ARB) actually has a mild uricosuric effect.
Option E: Option E is incorrect — the two classes have importantly different side effect profiles; the absence of cough with ARBs is clinically significant and is the main reason patients are switched from ACE inhibitors to ARBs.

9. Which of the following most accurately describes why beta-blockers are no longer considered first-line antihypertensive agents for uncomplicated hypertension in most current guidelines?

A) Beta-blockers are less effective at lowering blood pressure than other first-line agents — randomized controlled trials have shown that beta-blockers produce smaller reductions in systolic and diastolic BP compared to thiazides, ACE inhibitors, ARBs, and CCBs at equivalent doses
B) Beta-blockers are contraindicated in hypertension because their negative chronotropic effect reduces cardiac output to levels incompatible with adequate tissue perfusion at therapeutic doses
C) Beta-blockers are associated with inferior cardiovascular outcomes compared to other first-line classes in patients with uncomplicated hypertension — meta-analyses have shown that despite comparable BP lowering, beta-blockers (particularly atenolol) provide less stroke protection than would be predicted from the degree of BP reduction, and they have unfavorable metabolic effects including weight gain, glucose intolerance, and dyslipidemia; they retain a strong indication in hypertension complicated by heart failure with reduced EF, post-MI, or certain arrhythmias
D) Beta-blockers are renally cleared and cannot be used safely in the large proportion of hypertensive patients who have any degree of renal impairment
E) Beta-blockers cause excessive bradycardia in all patients with hypertension making them too dangerous for routine use in the outpatient setting

ANSWER: C

Rationale:

Beta-blockers were downgraded from first-line status based on outcome data rather than BP-lowering efficacy — meta-analyses demonstrated that atenolol in particular provided less stroke risk reduction than predicted from its BP-lowering effect compared to other classes; additionally, beta-blockers have metabolic consequences including weight gain, worsening insulin sensitivity, dyslipidemia (raising triglycerides and lowering HDL), and blunting of hypoglycemic symptoms in diabetic patients; however, beta-blockers retain compelling indications in hypertension with concurrent heart failure with reduced EF (where they improve mortality), post-MI (where they reduce reinfarction and mortality), and certain arrhythmias such as atrial fibrillation requiring rate control.

Option A: Option A is incorrect — beta-blockers are effective at lowering BP; the issue is cardiovascular outcome data relative to the degree of BP reduction, not BP-lowering efficacy per se.
Option B: Option B is incorrect — bradycardia is a dose-dependent effect that is monitored and managed, not a blanket reason for avoiding beta-blockers.
Option D: Option D is incorrect — while some beta-blockers are renally cleared (atenolol), others are hepatically metabolized (metoprolol, carvedilol) and can be used in renal impairment; renal clearance is not the basis for guideline demotion.
Option E: Option E is incorrect — beta-blockers at therapeutic doses do not reduce cardiac output to levels causing tissue hypoperfusion; the heart rate and contractility reduction is physiologically tolerated in most patients.

10. A patient with hypertension and type 2 diabetes with a urine albumin-to-creatinine ratio of 180 mg/g is started on antihypertensive therapy. Which drug class provides the strongest evidence for renoprotection beyond BP lowering in this patient?

A) Thiazide diuretics — chlorthalidone has the strongest evidence for renal protection in diabetic nephropathy through its volume-reducing effect which specifically reduces intraglomerular pressure
B) Dihydropyridine CCBs — amlodipine has been shown in multiple trials to reduce progression of diabetic nephropathy more effectively than ACE inhibitors through its efferent arteriolar vasodilatory effect
C) Mineralocorticoid receptor antagonists — spironolactone is the preferred first-line agent in diabetic nephropathy because aldosterone-mediated renal fibrosis is the primary driver of progression and blocking it provides superior renoprotection to RAAS inhibition
D) Beta-blockers — carvedilol has the strongest evidence for renoprotection in diabetic nephropathy through its combined alpha and beta blocking properties that reduce renal sympathetic tone
E) ACE inhibitors or ARBs — RAAS inhibition reduces intraglomerular pressure through efferent arteriolar dilation, decreases proteinuria, and has been shown in landmark trials (RENAAL with losartan, IDNT with irbesartan, MICRO-HOPE with ramipril) to slow progression of diabetic nephropathy independent of their BP-lowering effect; in a patient with hypertension, diabetes, and albuminuria this is a compelling indication for RAAS inhibition

ANSWER: E

Rationale:

ACE inhibitors and ARBs have the strongest evidence for renoprotection in diabetic nephropathy with albuminuria — the mechanism is dual: reduction of systemic BP and selective dilation of the efferent arteriole (which lowers intraglomerular hydraulic pressure and reduces the mechanical stress driving proteinuria); landmark trials demonstrated this benefit: the RENAAL trial (losartan reduced doubling of creatinine, ESRD, and death in type 2 diabetic nephropathy), IDNT trial (irbesartan superior to amlodipine and placebo for renal endpoints despite similar BP), and MICRO-HOPE (ramipril reduced overt nephropathy in diabetics); current guidelines recommend RAAS inhibition as first-line in hypertensive patients with diabetes and albuminuria.

Option A: Option A is incorrect — thiazides are useful antihypertensives in diabetes but do not have specific evidence for renoprotection beyond BP lowering in diabetic nephropathy.
Option B: Option B is incorrect — the IDNT trial specifically showed that irbesartan (ARB) was superior to amlodipine for renal endpoints despite similar BP reduction, establishing that the RAAS inhibition effect is independent of and superior to CCB-mediated BP lowering for renoprotection.
Option D: Option D is incorrect — carvedilol has outcome data in heart failure but not established superiority for renoprotection in diabetic nephropathy.
Option C: Option C is incorrect — while finerenone (a non-steroidal MRA) has emerging evidence in diabetic kidney disease (FIDELIO-DKD, FIGARO-DKD), mineralocorticoid antagonists are not first-line and hyperkalemia risk in CKD limits their use; RAAS inhibition remains the established first-line renoprotective strategy.

11. A 58-year-old man with hypertension and a history of gout is being evaluated for antihypertensive therapy. Which of the following best describes how thiazide diuretics affect uric acid metabolism and why this matters in this patient?

A) Thiazide diuretics lower uric acid levels by increasing renal uric acid excretion — they are therefore preferred in patients with gout because they provide antihypertensive benefit while also treating hyperuricemia
B) Thiazide diuretics have no effect on uric acid metabolism and are safe to use in patients with gout without any special consideration
C) Thiazide diuretics raise uric acid levels through volume contraction-mediated increases in proximal tubular uric acid reabsorption and competition with uric acid for organic anion secretion in the proximal tubule; hyperuricemia can precipitate or worsen gout; thiazides should be used with caution in patients with gout and an alternative antihypertensive class should be considered; notably losartan (an ARB) has a mild uricosuric effect and may be preferable in hypertensive patients with gout
D) Thiazide diuretics raise uric acid levels through direct inhibition of xanthine oxidase, increasing purine catabolism and uric acid production
E) Thiazide diuretics raise uric acid levels by blocking renal tubular secretion of uric acid through competitive inhibition of URAT1, the primary urate reabsorption transporter in the proximal tubule

ANSWER: C

Rationale:

Thiazide diuretics raise serum uric acid levels through two mechanisms — volume contraction from natriuresis increases proximal tubular reabsorption of uric acid as a consequence of enhanced overall proximal solute reabsorption; additionally, thiazides and uric acid compete for organic anion secretory pathways in the proximal tubule, reducing uric acid secretion; the net effect is hyperuricemia; in a patient with established gout, thiazide use can precipitate acute gout attacks and worsen the underlying condition; losartan among ARBs has a unique mild uricosuric effect through inhibition of URAT1 (the urate reabsorber) independent of its RAAS effects, making it a clinically useful choice in hypertensive patients with gout or hyperuricemia.

Option A: Option A is incorrect — thiazides raise, not lower, uric acid levels; they are not preferred in gout.
Option B: Option B is incorrect — thiazides do meaningfully affect uric acid and this is clinically relevant in patients with gout.
Option D: Option D is incorrect — thiazides do not inhibit xanthine oxidase; xanthine oxidase inhibition is the mechanism of allopurinol.
Option E: Option E is incorrect — the mechanism involves volume contraction and competition for organic anion secretion, not direct URAT1 blockade; URAT1 blockade is the mechanism of uricosuric agents like probenecid and is how losartan exerts its uricosuric effect.

12. Which of the following most accurately explains why dihydropyridine CCBs cause peripheral edema?

A) Dihydropyridine CCBs cause precapillary arteriolar dilation without equivalent venodilation — the resulting increase in capillary hydrostatic pressure in dependent tissues drives fluid transudation into the interstitium; this is not true fluid retention and does not respond well to diuretics; RAAS inhibitors (ACE inhibitors or ARBs) partially counteract this by dilating the venous side
B) Dihydropyridine CCBs block calcium channels in renal tubular cells, impairing sodium excretion and causing systemic fluid retention that manifests as dependent edema
C) Dihydropyridine CCBs cause sodium and water retention through activation of the RAAS — the drop in BP stimulates renin release, raising aldosterone and causing fluid accumulation in peripheral tissues
D) Dihydropyridine CCBs cause hypoalbuminemia through reduced hepatic protein synthesis, lowering oncotic pressure and allowing fluid to accumulate in interstitial spaces
E) Dihydropyridine CCBs cause lymphatic obstruction in the lower extremities through calcium channel blockade in lymphatic smooth muscle, impairing lymphatic drainage

ANSWER: A

Rationale:

CCB-induced peripheral edema is caused by selective precapillary arteriolar dilation without equivalent dilation of postcapillary venules — the resulting reduction in precapillary resistance increases capillary hydrostatic pressure in dependent tissues, driving fluid transudation into the interstitium; this is not sodium-mediated true fluid retention (total body sodium is not increased) and therefore does not respond well to diuretics; ACE inhibitors and ARBs reduce CCB-associated edema by dilating venules and reducing the venous hydrostatic pressure gradient; this mechanism explains why the combination of a CCB with an ACE inhibitor or ARB (as in the ACCOMPLISH trial) produces less edema than CCB monotherapy.

Option C: Option C is incorrect — while RAAS activation does contribute to some fluid retention with CCBs, the primary mechanism of dependent edema is the hemodynamic imbalance of arteriolar versus venous dilation described above, not primarily aldosterone-mediated retention.
Option B: Option B is incorrect — CCBs do not have meaningful effects on renal tubular sodium handling at therapeutic concentrations; they do not cause systemic fluid retention through this mechanism.
Option D: Option D is incorrect — CCBs do not cause hypoalbuminemia through hepatic effects; this is not a recognized mechanism of CCB edema.
Option E: Option E is incorrect — lymphatic obstruction is not the mechanism; the edema is hydrostatic in origin.

13. A patient with hypertension and chronic obstructive pulmonary disease (COPD) requires antihypertensive therapy. Which drug class carries a specific contraindication in this patient and why?

A) ACE inhibitors are contraindicated in COPD because bradykinin accumulation causes bronchoconstriction that worsens airflow obstruction and is indistinguishable from an acute COPD exacerbation
B) Thiazide diuretics are contraindicated in COPD because metabolic alkalosis from thiazide-induced hydrogen ion loss blunts the hypercapnic respiratory drive that COPD patients depend on for ventilation
C) Dihydropyridine CCBs are contraindicated in COPD because L-type calcium channel blockade in bronchial smooth muscle impairs the calcium-dependent bronchodilation that maintains airway patency in COPD patients
D) Non-selective beta-blockers are contraindicated in COPD and significant asthma because beta-2 receptor blockade in bronchial smooth muscle causes bronchoconstriction and can precipitate bronchospasm; cardioselective beta-1 blockers carry a relative contraindication and should be used with caution at low doses if a beta-blocker is required for a compelling indication such as heart failure or post-MI
E) ARBs are contraindicated in COPD because AT1 receptor blockade in the pulmonary vasculature causes pulmonary vasoconstriction that worsens ventilation-perfusion mismatch in patients with already-compromised lung function

ANSWER: D

Rationale:

Non-selective beta-blockers (propranolol, nadolol, carvedilol) are specifically contraindicated in COPD and asthma — beta-2 receptors in bronchial smooth muscle normally mediate bronchodilation; blocking them with a non-selective beta-blocker causes bronchoconstriction that can precipitate severe bronchospasm; cardioselective beta-1 blockers (metoprolol, bisoprolol, atenolol) have relative contraindication in significant obstructive lung disease — they are more selective for beta-1 but this selectivity is not absolute and diminishes at higher doses; when a beta-blocker is absolutely required (e.g., HFrEF, recent MI), a cardioselective agent at the lowest effective dose with careful monitoring is the approach.

Option A: Option A is incorrect — ACE inhibitor cough is a bradykinin-mediated airway irritation effect but does not cause bronchoconstriction or worsen airflow obstruction; while the cough can be troublesome and difficult to distinguish from respiratory symptoms in COPD patients, ACE inhibitors are not contraindicated in COPD.
Option B: Option B is incorrect — thiazide-induced metabolic alkalosis is a recognized but rarely clinically significant effect; it is not a contraindication in COPD and does not meaningfully blunt hypercapnic drive at usual therapeutic doses.
Option C: Option C is incorrect — dihydropyridine CCBs do not cause bronchoconstriction and are safe in COPD; L-type calcium channel blockade in bronchial smooth muscle would if anything produce mild bronchodilation.
Option E: Option E is incorrect — ARBs are safe in COPD and pulmonary vascular disease; AT1 blockade does not cause pulmonary vasoconstriction.

14. Which of the following most accurately explains why ACE inhibitors and ARBs are contraindicated in pregnancy?

A) ACE inhibitors and ARBs are contraindicated in pregnancy because they cause maternal hypotension severe enough to reduce uteroplacental perfusion and cause fetal growth restriction in all exposed pregnancies
B) ACE inhibitors and ARBs block fetal RAAS activity that is essential for normal renal development — fetal kidneys depend on angiotensin II for normal tubular development and renal blood flow regulation; blockade causes fetal renal tubular dysplasia, oligohydramnios from fetal anuria, pulmonary hypoplasia, limb contractures, and skull ossification defects; these effects are most severe in the second and third trimesters but exposure should be avoided throughout pregnancy
C) ACE inhibitors are contraindicated in pregnancy but ARBs are safe because ARBs block only the AT1 receptor while leaving AT2 receptor-mediated fetal developmental signaling intact
D) ACE inhibitors and ARBs are contraindicated only in the first trimester because organogenesis is complete by 12 weeks and the fetal RAAS is not active until the second trimester making later exposure safe
E) ACE inhibitors and ARBs are contraindicated in pregnancy because they cross the placenta and directly inhibit fetal cardiac ACE causing congenital heart defects in a dose-dependent manner

ANSWER: B

Rationale:

ACE inhibitors and ARBs are FDA category X contraindicated in pregnancy — the fetal RAAS is active from early gestation and plays a critical role in renal tubular development and maintenance of fetal renal blood flow; RAAS blockade causes fetal renal tubular dysplasia leading to impaired urine production, oligohydramnios, and its sequelae including pulmonary hypoplasia (from reduced amniotic fluid for lung development), fetal limb contractures, and calvarial ossification defects (skull bones become thin and compressible from reduced amniotic fluid pressure); these effects are most severe with second and third trimester exposure but avoidance throughout pregnancy is recommended; safe alternatives include methyldopa, labetalol, and extended-release nifedipine.

Option A: Option A is incorrect — while maternal hypotension is a concern with any antihypertensive in pregnancy, the specific fetal toxicity of RAAS inhibitors is through direct fetal RAAS blockade, not through maternal hemodynamic effects alone.
Option C: Option C is incorrect — both ACE inhibitors and ARBs are contraindicated in pregnancy; AT2 receptor signaling does not protect the fetus from AT1 blockade with ARBs, and both classes impair fetal renal development through their RAAS-blocking effects.
Option D: Option D is incorrect — the old guidance suggesting first-trimester relative safety has been revised; RAAS inhibitors should be avoided throughout pregnancy; the fetal RAAS is active from early gestation and first-trimester exposure may also cause harm.
Option E: Option E is incorrect — congenital heart defects through cardiac ACE inhibition are not the established mechanism of fetal toxicity; the renal developmental pathway is the primary concern.

15. Chlorthalidone and hydrochlorothiazide are both thiazide-type diuretics used for hypertension. Which of the following most accurately describes a clinically important pharmacokinetic difference between them?

A) Chlorthalidone and hydrochlorothiazide have identical pharmacokinetics — they are bioequivalent agents and can be substituted for each other at the same dose without any clinical difference
B) Hydrochlorothiazide has a significantly longer half-life than chlorthalidone, providing smoother 24-hour BP control and making it the preferred agent in guidelines that emphasize 24-hour BP management
C) Chlorthalidone has a substantially longer half-life (approximately 45–60 hours) compared to hydrochlorothiazide (approximately 6–15 hours) — this provides more consistent 24-hour BP lowering with chlorthalidone, better nocturnal BP control, and a longer duration of action if a dose is missed; outcome trials demonstrating cardiovascular benefit (ALLHAT, SHEP) used chlorthalidone, not hydrochlorothiazide; many guidelines now prefer chlorthalidone for these reasons
D) Chlorthalidone is renally eliminated while hydrochlorothiazide is hepatically metabolized, making chlorthalidone the preferred agent in patients with liver disease and hydrochlorothiazide preferred in patients with CKD
E) Hydrochlorothiazide has greater bioavailability than chlorthalidone, producing higher peak plasma concentrations and more effective natriuresis at equivalent doses despite the shorter half-life

ANSWER: C

Rationale:

Chlorthalidone has a substantially longer half-life of approximately 45–60 hours compared to hydrochlorothiazide's 6–15 hours — this pharmacokinetic difference has important clinical consequences: chlorthalidone provides more consistent 24-hour BP control including better nocturnal BP reduction, which is particularly important since nocturnal hypertension and non-dipping patterns are associated with higher cardiovascular risk; the major outcome trials demonstrating cardiovascular benefit of thiazide-type diuretics (ALLHAT using chlorthalidone, SHEP using chlorthalidone) used chlorthalidone, not hydrochlorothiazide; there are no equivalent-powered outcome trials with hydrochlorothiazide; for these reasons major guidelines increasingly recommend chlorthalidone as the preferred thiazide-type diuretic.

Option A: Option A is incorrect — chlorthalidone and hydrochlorothiazide are not bioequivalent; they have substantially different half-lives and the outcome trial evidence base differs significantly.
Option B: Option B is incorrect — hydrochlorothiazide has the shorter half-life; chlorthalidone has the longer half-life and provides better 24-hour coverage.
Option D: Option D is incorrect — both agents are primarily renally eliminated; hepatic metabolism is not the distinguishing pharmacokinetic feature.
Option E: Option E is incorrect — bioavailability is not the clinically important distinction between these agents; half-life and duration of action are the key pharmacokinetic differences.

16. A 64-year-old Black man with hypertension and no other comorbidities requires antihypertensive therapy. His BP is 156/94 mmHg. Which of the following most accurately guides initial drug selection in this patient?

A) ACE inhibitors are the preferred first-line agent regardless of race or ethnicity — the renoprotective benefit of RAAS inhibition outweighs any considerations of differential response
B) Beta-blockers are preferred in Black patients with hypertension because they address the elevated sympathetic tone that is the primary driver of hypertension in this population
C) ACE inhibitors should be avoided entirely in Black patients because the risk of angioedema is so high that the benefit-risk ratio is unfavorable for any indication in this population
D) Dihydropyridine CCBs are contraindicated in Black patients because of a higher rate of CCB-induced angioedema in this population compared to other racial groups
E) Thiazide diuretics or dihydropyridine CCBs are preferred as initial therapy in Black patients with uncomplicated hypertension — clinical trial data including ALLHAT demonstrated that Black patients have lower BP responses to ACE inhibitor monotherapy compared to thiazide diuretics and CCBs, likely related to lower renin activity and higher salt sensitivity in this population; when RAAS inhibitors are used they are more effective in combination with a thiazide or CCB; the preference for thiazides and CCBs as monotherapy does not apply when there is a compelling indication for RAAS inhibition such as diabetes with albuminuria or heart failure

ANSWER: E

Rationale:

Clinical trial data support preferring thiazide diuretics or dihydropyridine CCBs as initial monotherapy in Black patients with uncomplicated hypertension — ALLHAT demonstrated that chlorthalidone and amlodipine produced greater BP reduction than lisinopril in Black patients, and lisinopril was associated with higher rates of stroke in Black participants; the pharmacological explanation relates to the tendency toward lower plasma renin activity and greater volume/salt sensitivity in Black patients, making volume-depleting (thiazide) and direct vasodilatory (CCB) strategies more effective than RAAS inhibition as monotherapy; however, when a compelling indication exists (diabetes with albuminuria, HFrEF, post-MI) RAAS inhibitors are still indicated regardless of race.

Option A: Option A is incorrect — the differential response to ACE inhibitor monotherapy in Black patients is well-documented in ALLHAT and is clinically important for initial drug selection in uncomplicated hypertension.
Option B: Option B is incorrect — elevated sympathetic tone as a race-specific primary driver is not the established pharmacological rationale; lower renin activity and higher salt sensitivity are the more evidence-based explanations for differential drug response.
Option D: Option D is incorrect — CCBs are not contraindicated in Black patients; ACE inhibitors are associated with higher rates of angioedema in Black patients, not CCBs.
Option C: Option C is incorrect — ACE inhibitors are not contraindicated in Black patients; the higher angioedema risk (approximately 3–4 times the rate in white patients) requires awareness and informed consent but does not make the benefit-risk ratio uniformly unfavorable, particularly when compelling indications exist.

17. A patient with hypertension develops hyperkalemia (K+ 6.1 mEq/L) while on lisinopril. The physician wants to maintain RAAS blockade for a compelling indication. Which of the following most accurately describes the next pharmacological step?

A) Switch to an ARB — ARBs do not cause hyperkalemia because they block the AT1 receptor rather than inhibiting ACE, preventing the angiotensin II-mediated pathway that causes potassium retention
B) Add a potassium-wasting diuretic such as furosemide to lower potassium while continuing lisinopril — the loop diuretic will excrete enough potassium to offset the ACE inhibitor effect and maintain safe potassium levels
C) The hyperkalemia must be addressed — options include dose reduction of lisinopril, adding a thiazide or loop diuretic to increase potassium excretion, dietary potassium restriction, or initiating a potassium binder such as patiromer or sodium zirconium cyclosilicate; switching to an ARB would not resolve the hyperkalemia since both ACE inhibitors and ARBs raise potassium through RAAS blockade; the choice of intervention depends on the degree of hyperkalemia, renal function, and the urgency of maintaining RAAS inhibition
D) Discontinue lisinopril permanently — any RAAS inhibitor is permanently contraindicated after a single episode of hyperkalemia regardless of the underlying cause or potassium level
E) Switch to a direct renin inhibitor such as aliskiren — renin inhibition does not affect potassium homeostasis and can maintain RAAS blockade without any risk of hyperkalemia

ANSWER: C

Rationale:

Both ACE inhibitors and ARBs raise potassium through the same downstream mechanism — reduced angiotensin II lowers aldosterone secretion, reducing collecting duct potassium excretion; switching from an ACE inhibitor to an ARB would not resolve hyperkalemia because both classes produce equivalent degrees of aldosterone suppression and equivalent potassium retention; the appropriate management of ACE inhibitor-induced hyperkalemia includes dose reduction, addition of a kaliuretic diuretic (thiazide or loop diuretic), dietary potassium restriction, or use of potassium binders (patiromer, SZC) which specifically enable continued RAAS inhibition in patients with CKD or other conditions causing hyperkalemia.

Option A: Option A is incorrect — ARBs cause hyperkalemia through the same mechanism as ACE inhibitors (reduced aldosterone from RAAS blockade); switching classes does not resolve the problem.
Option B: Option B is incorrect — adding furosemide is a reasonable strategy to increase potassium excretion but it alone may not be sufficient at K+ 6.1 mEq/L and does not address the need for a comprehensive management plan.
Option D: Option D is incorrect — permanently discontinuing all RAAS inhibitors after a single episode of hyperkalemia is not appropriate; hyperkalemia is often manageable with dose reduction, dietary modification, diuretics, or potassium binders, allowing continued RAAS inhibition when there is a compelling indication.
Option E: Option E is incorrect — aliskiren (direct renin inhibitor) also blocks RAAS and raises potassium through the same downstream aldosterone suppression mechanism; it does not provide a hyperkalemia-free alternative for RAAS blockade.

18. The ALLHAT trial is frequently cited in guidelines for antihypertensive drug selection. Which of the following most accurately summarizes its key finding relevant to first-line drug choice?

A) ALLHAT demonstrated that ACE inhibitors are superior to thiazide diuretics and CCBs for prevention of all cardiovascular outcomes including stroke, coronary heart disease, and heart failure across all patient subgroups
B) ALLHAT demonstrated that chlorthalidone was at least as effective as lisinopril and amlodipine for the primary outcome of fatal coronary heart disease or nonfatal MI, and superior to lisinopril for stroke prevention in Black patients and superior to amlodipine for heart failure prevention; this established chlorthalidone as a cornerstone first-line agent and supported thiazide diuretics as preferred initial therapy in uncomplicated hypertension
C) ALLHAT demonstrated that amlodipine is superior to all other antihypertensive classes for stroke prevention and should be the preferred first-line agent in patients at high stroke risk regardless of other comorbidities
D) ALLHAT demonstrated that alpha-blockers (doxazosin) are equivalent to thiazide diuretics for all cardiovascular outcomes and should be considered equally as first-line agents in uncomplicated hypertension
E) ALLHAT demonstrated that combination therapy with two agents from different classes is always superior to monotherapy and established the two-drug regimen as the minimum standard for initial hypertension treatment

ANSWER: B

Rationale:

ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) compared chlorthalidone, amlodipine, lisinopril, and doxazosin in over 33,000 high-risk hypertensive patients — the primary outcome (fatal CHD or nonfatal MI) was similar across chlorthalidone, amlodipine, and lisinopril; however, chlorthalidone was superior to lisinopril for stroke (driven largely by the Black patient subgroup where lisinopril produced less BP lowering) and superior to amlodipine for heart failure prevention; the doxazosin arm was stopped early due to higher heart failure rates compared to chlorthalidone; the overall conclusion supported chlorthalidone as an effective, low-cost first-line agent and contributed to thiazide diuretics being recommended as preferred initial therapy in major guidelines.

Option A: Option A is incorrect — ALLHAT did not show ACE inhibitor superiority; chlorthalidone was equivalent or superior to lisinopril for several outcomes.
Option C: Option C is incorrect — ALLHAT specifically demonstrated that doxazosin (alpha-blocker) was inferior to chlorthalidone for heart failure prevention, leading to early termination of that arm; alpha-blockers are not recommended as first-line agents.
Option D: Option D is incorrect — amlodipine was not shown to be superior to chlorthalidone for stroke; chlorthalidone was superior to amlodipine for heart failure prevention.
Option E: Option E is incorrect — ALLHAT was a monotherapy comparison trial; it did not establish combination therapy as the minimum standard for initial treatment.

19. A 71-year-old woman with isolated systolic hypertension (BP 168/74 mmHg) and no other comorbidities is being considered for antihypertensive therapy. Which of the following most accurately characterizes the evidence base for treating isolated systolic hypertension in older adults?

A) Isolated systolic hypertension in patients over 70 should not be treated pharmacologically because the wide pulse pressure reflects arterial stiffness that is a normal physiological consequence of aging and lowering systolic BP risks reducing diastolic BP below safe perfusion levels for coronary and cerebral circulation
B) Treatment of isolated systolic hypertension in older adults is supported by landmark trials including SHEP (using chlorthalidone) and Syst-Eur (using nitrendipine, a dihydropyridine CCB) which demonstrated significant reductions in stroke, cardiovascular events, and mortality with antihypertensive treatment; thiazide diuretics and dihydropyridine CCBs are the best-evidenced drug classes for this indication; treatment should be initiated cautiously with gradual titration to avoid excessive BP reduction and orthostatic hypotension
C) Treatment of isolated systolic hypertension in patients over 70 is only beneficial if the diastolic BP is also elevated above 90 mmHg — a normal or low diastolic BP in this setting indicates that the systolic elevation is benign and does not require pharmacological intervention
D) ACE inhibitors are the preferred class for isolated systolic hypertension in elderly patients because renin activity is characteristically elevated in this condition and RAAS blockade specifically addresses the underlying pathophysiology
E) Isolated systolic hypertension in elderly patients should be treated only with beta-blockers because their negative chronotropic effect reduces the augmented pulse wave reflection that contributes to elevated systolic pressure in arterially stiff vessels

ANSWER: B

Rationale:

Treatment of isolated systolic hypertension in older adults is strongly evidence-based — the SHEP trial (Systolic Hypertension in the Elderly Program) demonstrated that chlorthalidone-based therapy reduced stroke by 36% and cardiovascular events significantly in patients over 60 with isolated systolic hypertension; the Syst-Eur trial demonstrated similar benefits with nitrendipine (a dihydropyridine CCB); these trials established that the cardiovascular risk of elevated systolic BP in older adults is real and modifiable; treatment should be initiated at low doses with careful titration to avoid orthostatic hypotension, which is more common in older patients; a BP target of below 130/80 mmHg (2017 ACC/AHA) or below 140/90 mmHg (older guidelines) applies based on individual risk.

Option A: Option A is incorrect — withholding treatment based on the rationale that systolic hypertension is a normal aging phenomenon is not supported by the evidence; SHEP and Syst-Eur clearly demonstrated treatment benefit; while careful titration to avoid low diastolic BP is appropriate, this does not mean treatment should be withheld.
Option C: Option C is incorrect — isolated systolic hypertension with a normal diastolic is not benign; the trial evidence applies specifically to this pattern and demonstrates clear cardiovascular benefit from treatment regardless of diastolic BP level.
Option D: Option D is incorrect — renin activity is typically low in isolated systolic hypertension of the elderly (a volume/stiffness-driven condition), making ACE inhibitors less effective as monotherapy; thiazides and CCBs have the strongest trial evidence.
Option E: Option E is incorrect — beta-blockers are less effective at reducing central aortic pressure relative to brachial pressure in older patients with arterial stiffness; they are not the preferred class for isolated systolic hypertension in the elderly.

20. A patient with hypertension and heart failure with reduced ejection fraction (HFrEF, EF 35%) requires antihypertensive and heart failure therapy. Which antihypertensive drug class is specifically contraindicated in this patient?

A) ACE inhibitors — they reduce afterload but increase preload through sodium retention, worsening ventricular filling pressure in HFrEF
B) Beta-blockers — their negative inotropic effect reduces cardiac output in an already failing heart and they should be avoided in all patients with HFrEF
C) Non-dihydropyridine calcium channel blockers (verapamil and diltiazem) — these agents have significant negative inotropic effects that can precipitate acute decompensation in HFrEF with reduced systolic function; dihydropyridine CCBs such as amlodipine are safe in HFrEF and can be used for BP control
D) Thiazide diuretics — they cause volume depletion that reduces preload below the level required for adequate cardiac output in HFrEF, making them specifically contraindicated in this condition
E) ARBs — AT1 receptor blockade in the failing myocardium eliminates the compensatory angiotensin II effect that maintains contractile function in HFrEF, causing acute decompensation

ANSWER: C

Rationale:

Non-dihydropyridine CCBs — verapamil and diltiazem — are specifically contraindicated in HFrEF because of their significant negative inotropic effects; in a patient with already-impaired systolic function, the reduction in myocardial contractility from these agents can precipitate acute hemodynamic decompensation; dihydropyridine CCBs (amlodipine, felodipine) have minimal negative inotropic effect and are safe in HFrEF — amlodipine was specifically studied in the PRAISE trials in HFrEF patients and was found to be safe; for BP control in HFrEF the preferred agents are ACE inhibitors/ARBs, beta-blockers (which are specifically indicated for mortality benefit in HFrEF), and loop diuretics for volume management.

Option A: Option A is incorrect — ACE inhibitors are a cornerstone of HFrEF therapy; they reduce afterload, decrease adverse cardiac remodeling, and have a mortality benefit demonstrated in multiple trials (CONSENSUS, SOLVD); they do not worsen HFrEF.
Option B: Option B is incorrect — beta-blockers are specifically indicated in stable HFrEF with mortality benefit (MERIT-HF with metoprolol succinate, COPERNICUS with carvedilol, CIBIS-II with bisoprolol); they are initiated at low doses and titrated cautiously in stable patients.
Option D: Option D is incorrect — thiazide diuretics can be used in HFrEF for BP control though loop diuretics are generally preferred for volume management in advanced HFrEF; thiazides are not specifically contraindicated.
Option E: Option E is incorrect — ARBs are indicated as alternatives to ACE inhibitors in HFrEF (CHARM-Alternative with candesartan); they do not cause acute decompensation through the mechanism described.

21. A 45-year-old woman with hypertension, migraines, and no other comorbidities asks whether her antihypertensive medication can also help prevent her migraines. Which of the following most accurately addresses this dual-purpose consideration?

A) Dihydropyridine CCBs such as amlodipine are the preferred dual-purpose agent — they prevent migraines by blocking calcium-mediated cortical spreading depression and their antihypertensive effect addresses the vascular component of migraine pathophysiology
B) Thiazide diuretics are preferred for migraine prevention in hypertensive patients because volume reduction decreases intracranial pressure which is the primary driver of migraine headache
C) ACE inhibitors are contraindicated in migraine patients because bradykinin accumulation triggers trigeminovascular activation, worsening migraine frequency and severity
D) Beta-blockers (particularly propranolol and metoprolol) and certain CCBs (verapamil) have established evidence for migraine prevention — propranolol is FDA-approved for migraine prophylaxis; beta-blockers may prevent migraines through reduction of sympathetic activity, central serotonin modulation, or effects on cortical excitability; selecting a beta-blocker as the antihypertensive in this patient provides dual benefit; ACE inhibitors and ARBs (particularly candesartan and lisinopril) also have supporting evidence for migraine prevention
E) No antihypertensive class has evidence for migraine prevention — migraine prophylaxis requires separate dedicated therapy with topiramate or amitriptyline regardless of blood pressure status

ANSWER: D

Rationale:

Beta-blockers have the strongest evidence for migraine prevention among antihypertensive classes — propranolol and timolol are FDA-approved for migraine prophylaxis; metoprolol has evidence from multiple trials; the mechanism is not fully established but likely involves central beta-adrenergic effects reducing cortical excitability and sympathetic modulation; for a hypertensive patient with migraines, selecting a beta-blocker as the antihypertensive provides dual benefit; verapamil (non-dihydropyridine CCB) has evidence for cluster headache prevention; candesartan (ARB) and lisinopril (ACE inhibitor) have supporting evidence for migraine prevention in smaller trials making RAAS inhibitors a reasonable secondary choice; dihydropyridine CCBs like amlodipine do not have established migraine prevention evidence.

Option A: Option A is incorrect — dihydropyridine CCBs including amlodipine do not have established evidence for migraine prevention; this is a common misconception; verapamil (non-dihydropyridine) has evidence for cluster headache.
Option B: Option B is incorrect — thiazide diuretics do not have evidence for migraine prevention through any mechanism; intracranial pressure reduction is not the migraine prevention mechanism relevant here.
Option C: Option C is incorrect — ACE inhibitors (lisinopril specifically) have evidence supporting migraine prevention, not worsening; bradykinin accumulation from ACE inhibitors causes cough, not migraine exacerbation.
Option E: Option E is incorrect — multiple antihypertensive classes have supporting evidence for migraine prevention; the statement that no antihypertensive has such evidence is factually incorrect.

22. A patient on a stable antihypertensive regimen begins taking ibuprofen regularly for arthritis pain. His BP rises from 128/78 to 148/92 mmHg over 4 weeks. Which of the following most accurately explains this interaction?

A) Ibuprofen raises BP by directly activating alpha-1 adrenergic receptors in vascular smooth muscle, causing vasoconstriction that is additive to his baseline hypertension
B) Ibuprofen raises BP exclusively through inhibition of ACE inhibitor activity — it competitively blocks ACE inhibitor binding to angiotensin-converting enzyme, reducing the antihypertensive effect
C) Ibuprofen raises BP through selective COX-2 inhibition that upregulates thromboxane A2 production in platelets causing systemic vasoconstriction; this effect is specific to ibuprofen and does not occur with other NSAIDs
D) Ibuprofen inhibits prostaglandin synthesis through COX-1 and COX-2 inhibition — renal prostaglandins normally maintain afferent arteriolar dilation and support natriuresis; their inhibition causes sodium and water retention, reduces renal blood flow, and blunts the antihypertensive effect of multiple drug classes; this interaction is particularly significant with ACE inhibitors, ARBs, and diuretics but affects virtually all antihypertensive classes to some degree; the clinical consequence is a rise in BP that reverses when the NSAID is discontinued
E) Ibuprofen has no direct effect on BP — the BP rise reflects natural disease progression unrelated to the NSAID and the temporal correlation is coincidental

ANSWER: D

Rationale:

NSAIDs including ibuprofen antagonize antihypertensive therapy through prostaglandin inhibition — renal prostaglandins (PGE2, PGI2) are locally produced vasodilators that maintain afferent arteriolar tone and promote natriuresis; COX inhibition reduces these prostaglandins, causing afferent arteriolar constriction, sodium and water retention, and reduced renal blood flow; these effects blunt the BP-lowering effects of diuretics (by reducing natriuresis), ACE inhibitors and ARBs (by independently raising BP through volume expansion), and CCBs (by increasing SVR); the average BP rise with regular NSAID use in hypertensive patients is approximately 3–5 mmHg but can be larger in individual patients; acetaminophen is preferred for analgesia in hypertensive patients when anti-inflammatory activity is not required.

Option A: Option A is incorrect — ibuprofen does not directly activate alpha-1 adrenergic receptors; its BP-raising effect is through prostaglandin inhibition and consequent sodium retention.
Option B: Option B is incorrect — ibuprofen does not competitively inhibit ACE inhibitor binding to ACE; the interaction is pharmacodynamic through prostaglandin inhibition, not pharmacokinetic.
Option C: Option C is incorrect — ibuprofen inhibits both COX-1 and COX-2; the description of selective COX-2 inhibition is more applicable to celecoxib; and systemic vasoconstriction through thromboxane A2 is not the primary mechanism of NSAID-induced hypertension.
Option E: Option E is incorrect — the temporal correlation between NSAID initiation and BP rise over 4 weeks is clinically and pharmacologically explained; this interaction is well-documented and the BP elevation is expected to reverse when the NSAID is stopped.

BEFORE YOU MOVE ON

You have reviewed the mechanisms, adverse effects, key contraindications, and clinical selection rationale for the five first-line antihypertensive drug classes. Tier 1 will test this knowledge in more complex clinical scenarios — patients with multiple comorbidities, drug interactions, and competing considerations where mechanism-based reasoning determines the right choice. Make sure you can explain not just which drug to use, but why the mechanism makes it the right or wrong choice in a given patient.